News Release Detail

April 30, 2002

Mylan Laboratories Inc. Announces Fiscal 2002 Fourth Quarter and Year End Earnings Release Date and Conference Call

Mylan Laboratories Inc. Announces Fiscal 2002 Fourth Quarter and Year End Earnings Release Date and Conference CallPITTSBURGH, Apr 30, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that it will release its fiscal 2002 fourth quarter and full year financial results before the market opens on Wednesday, May 8, 2002.

Mylan management will host a conference call and provide a live webcast later that morning at 10:00 AM EDT to discuss the financial results and relevant company topics. The dial-in-number to access this call is (719)-457-2600. A replay of the conference call will be available from approximately 12:00 PM EDT on May 8, through 12:00 PM EDT May 15, and can be accessed by dialing (719)-457-0820 with access pass code 578535.

To access the live Webcast, go to Mylan's website at www.mylan.com and click on the Webcast icon at least 15 minutes before the call is to begin to register and download or install any necessary audio software. If you are unable to listen to the live webcast, please access www.mylan.com at any time within seven days to listen to a replay of the Webcast.

Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets generic and proprietary prescription pharmaceutical products. The Company markets an extensive line of generic products through its three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc., as well as branded products through its Bertek Pharmaceuticals Inc. subsidiary. For more information, visit www.mylan.com.

CONTACT:          Mylan Laboratories Inc.
                  Patricia Sunseri, 412-232-0100

URL:              http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire.  All rights reserved.
Email Alerts
Investor FAQs
Contact Us
LinkedIn